arrow
H

H. Moses Murdock

Harvard Medical School
H指数:14
被引数:1,183

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Venetoclax-augmented RIC allogeneic HCT with PTCy-based GVHD prophylaxis and venetoclax/azacitidine maintenance for poor risk MDS and AML

维奈克拉增强的RIC同种异基因HCT联合PTCy为基础的GVHD预防及维奈克拉/阿扎胞苷维持治疗高危MDS和AML

2026-08-190
OAAI
CPX-351 Selectively Benefits Patients with AML and Myelodysplasia-Related Mutations in the Pivotal Randomized Trial

在关键性随机试验中,CPX-351选择性地使AML和脊髓发育不良相关突变患者受益

2026-02-040
OAAI
Venetoclax/FluBu2 RIC transplant followed by all-oral venetoclax/decitabine maintenance for poor risk MDS/AML

Venetoclax/FluBu2 缓和性化疗移植后,采用全口服 venetoclax/decitabine 维持治疗高危 MDS/AML

2025-12-090
OAAI
No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapse

自造血干细胞移植(HCT)后复发急性髓系白血病(AML)并达到缓解的患者,细胞疗法巩固治疗并无明确益处。

2025-11-040
OAAI
Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML
2024-02-165
OAAI
Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group's clinical trial E3999 (vol 12, 137,2022)
2023-07-060
OAAI
Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group's clinical trial E3999
2022-09-232
OAAI
BCOR and BCORL1 Mutations Drive Epigenetic Reprogramming and Oncogenic Signaling by Unlinking PRC1.1 from Target Genes
2022-03-0425
OA
Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active
2021-12-1729
OAAI
Genomic and evolutionary portraits of disease relapse in acute myeloid leukemia
LEUKEMIA
IF13.4
2021-02-1210
OAAI
Recurrent rhinovirus infections in a child with inherited MDA5 deficiency
2017-06-12102
OAAI